A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
Clinical trial NCT06672068 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06672068
- Sponsor
- TYK Medicines, Inc
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-20
- Primary completion
- 2027-12-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.